Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 80 years of age
• People who have been diagnosed with an acute ischemic stroke (a stroke caused by a blocked blood vessel) based on clinical and imaging assessments, following Chinese stroke diagnosis guidelines (2023)
• People whose stroke has been confirmed within 72 hours of it starting to be caused by a build-up of fatty deposits in large blood vessels (a specific stroke subtype)
• People whose stroke severity, measured by a standard medical scale called the NIHSS, falls between 4 and 20 before treatment begins
• People who were largely independent before their stroke, with a disability score of 1 or less on a standard scale (called the modified Rankin Scale)
• People whose LDL cholesterol level (often called "bad cholesterol") is 1.8 mmol/L or higher at the time of enrolment
• People who are able to take the study medication (evolocumab) and a cholesterol-lowering statin as directed by the treating doctor
• People who have not previously used a type of cholesterol-lowering medication called a PCSK9 inhibitor
• People who have provided written consent to participate, either themselves or through a legally authorised representative

Who may not be able to join:

• People who have bleeding into or around the brain (such as a bleed within the stroke area, bleeding around the brain, or blood clots pressing on the brain), except for very small, incidentally detected micro-bleeds seen only on a specific type of brain scan
• People who have already had a procedure to open blocked blood vessels in the brain or neck before enrolment, those for whom such a procedure is planned within 90 days, or those with planned surgery that could affect how results are measured
• People with severe heart failure classified as Class III or IV on a standard medical scale (meaning significant limitations on physical activity or symptoms even at rest)
• People with seriously reduced liver function (based on specific blood test results) or seriously reduced kidney function (based on kidney filtering rate or need for dialysis)
• People with a low platelet count (the blood cells that help clotting), below a specific threshold on a blood test
• People who are pregnant or breastfeeding
• People who have taken part in another interventional clinical trial within the 30 days before enrolment, or who are currently in another interventional trial that could affect how results are measured
• People with a large brain tumour, a large brain aneurysm (a bulge in a blood vessel), or an abnormal tangle of blood vessels in the brain
• People with an active stomach or intestinal ulcer, a tendency to bleed (based on specific blood test results or a history of a condition called heparin-induced thrombocytopenia), or a major bleeding episode anywhere in the body within the 30 days before enrolment
• People with a pre-existing neurological or psychiatric condition likely to affect how outcomes are measured, a severe neurological disability that has already caused loss of independent living, or dementia or psychiatric illness that would prevent completing follow-up
• People with an autoimmune disease, such as lupus, Sjögren's syndrome, Behçet's disease, systemic sclerosis, mixed connective tissue disease, or IgG4-related disease
• People with active seizures, low blood pressure, an overactive thyroid, asthma, other allergic breathing conditions, or a known tendency toward allergic reactions
• People whom the trial investigator considers unsuitable for participation for any other reason, or for whom participation would pose a significant risk

Important: Always verify eligibility with the trial site directly before applying.